Results 101 to 110 of about 142,198 (255)

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Arrhythmia Diagnosis Following an ICD Shock.

Indian Pacing and Electrophysiology Journal, 2001
Stored electrograms show atrial fibrillation with rapid ventricular rates (top panel). Sufficient numbers of RR intervals meet the tachycardia detection criteria initiating a train of anti-tachycardia pacing by the ICD (after the 8th electrogram in the ...
Roy M. John
doaj  

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Ventricular fibrillation [PDF]

, 2020
Sonam Vadera, Daniel Bell
openaire   +2 more sources

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source